Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
2010; Massachusetts Medical Society; Volume: 363; Issue: 3 Linguagem: Inglês
10.1056/nejmoa0909905
ISSN1533-4406
AutoresJohn H. Stone, Peter A. Merkel, Robert Spiera, Philip Seo, Carol A. Langford, Gary S. Hoffman, Cees G. M. Kallenberg, E. William St. Clair, Anthony Turkiewicz, Nadia K. Tchao, Lisa Webber, Linna Ding, Lourdes P. Sejismundo, Kathleen Mieras, David Weitzenkamp, David Iklé, Vicki Seyfert‐Margolis, Mark Mueller, Paul Brunetta, Nancy B. Allen, Fernando C. Fervenza, Duvuru Geetha, Karina A. Keogh, Eugene Y. Kissin, Paul A. Monach, Tobias Peikert, Coen A. Stegeman, Steven R. Ytterberg, Ulrich Specks,
Tópico(s)Heparin-Induced Thrombocytopenia and Thrombosis
ResumoCyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen.
Referência(s)